PROSTATE HEALTH — COMMUNITY PHARMACIST GUIDE CLINICAL REFERENCE 2025
PROSTATE HEALTH
Comprehensive Management Guide
A practical, evidence-based clinical reference for Community Pharmacists
covering PSA interpretation, BPH & prostate cancer pharmacotherapy,
non-pharmacological strategies, lifestyle medicine, and patient counselling.
Intended For Community Pharmacists & Healthcare Professionals
Scope BPH • Prostatitis • Prostate Cancer Supportive Care
Edition 2025 | Evidence-Based Clinical Practice
For professional use only. Always individualise therapy. Refer appropriately. Page 1
PROSTATE HEALTH — COMMUNITY PHARMACIST GUIDE CLINICAL REFERENCE 2025
TABLE OF CONTENTS
1. Understanding PSA — Interpretation & Clinical Context
2. Prostate Conditions Overview
3. Benign Prostatic Hyperplasia (BPH) — Full Management
4. Prostatitis — Types & Treatment
5. Prostate Cancer — Pharmacist's Perspective
6. Non-Pharmacological Interventions
7. Lifestyle Modifications
8. Dietary & Nutraceutical Guidance
9. Patient Counselling Framework
10. Monitoring & Follow-up
11. Red Flags & Referral Triggers
12. Quick-Reference Drug Tables
For professional use only. Always individualise therapy. Refer appropriately. Page 2
PROSTATE HEALTH — COMMUNITY PHARMACIST GUIDE CLINICAL REFERENCE 2025
1. UNDERSTANDING PSA — INTERPRETATION & CLINICAL
CONTEXT
Prostate-Specific Antigen (PSA) is a glycoprotein serine protease produced exclusively by prostate epithelial cells.
It is the most widely used biomarker for prostate disease, though elevated levels are NOT diagnostic of cancer
alone — they require clinical correlation.
PSA Reference Ranges (Age-Stratified)
Age Group Normal PSA (ng/mL) Borderline Action Threshold
40–49 yrs < 2.5 2.5 – 4.0 > 4.0 → Urology referral
50–59 yrs < 3.5 3.5 – 4.0 > 4.0 → Biopsy discussion
60–69 yrs < 4.5 4.5 – 6.5 > 6.5 → Urgent referral
70+ yrs < 6.5 6.5 – 8.0 > 8.0 → Urgent referral
Key PSA Derivatives — More Nuanced Assessment
Metric Formula / Threshold Clinical Significance
PSA Density PSA ÷ Prostate Volume > 0.15 ng/mL/cc raises cancer suspicion
PSA Velocity Rise > 0.75 ng/mL/yr Rapid rise more concerning than absolute level
Free/Total PSA Ratio % Free PSA < 10% → high cancer risk; > 25% → low risk
PSA Doubling Time < 3 months rapid Indicator of aggressive disease progression
Pharmacist Note: PSA can be falsely elevated by UTI, prostatitis, urinary catheterisation, vigorous cycling, or
ejaculation within 48 hours. Advise patients to avoid these before testing. Also: 5-alpha reductase inhibitors
(finasteride, dutasteride) lower PSA by ~50% — adjust interpretation accordingly.
For professional use only. Always individualise therapy. Refer appropriately. Page 3
PROSTATE HEALTH — COMMUNITY PHARMACIST GUIDE CLINICAL REFERENCE 2025
2. PROSTATE CONDITIONS OVERVIEW
The prostate gland sits below the bladder and surrounds the urethra. Three main pathological conditions arise, all
presenting with overlapping LUTS (Lower Urinary Tract Symptoms):
Condition Age Group PSA Pattern Key Feature
BPH (Benign Prostatic Hyperplasia) 50+ (common) Mildly elevated Obstructive + irritative LUTS; benign
Prostatitis (Bacterial/CPPS) Any age Often elevated Pelvic pain, dysuria; may be chronic
Prostate Cancer 60+ typically Elevated/rising Asymmetric hard gland on DRE; possible mets
Your patient's presentation — persistent urinary incontinence after UTI/STI treatment — is highly consistent with
BPH or early prostate pathology. The PSA result will help stratify risk. This guide covers all three conditions
comprehensively.
For professional use only. Always individualise therapy. Refer appropriately. Page 4
PROSTATE HEALTH — COMMUNITY PHARMACIST GUIDE CLINICAL REFERENCE 2025
3. BENIGN PROSTATIC HYPERPLASIA (BPH) — FULL
MANAGEMENT
BPH is the non-malignant proliferation of prostatic stromal and epithelial cells, resulting in bladder outlet
obstruction. It affects ~50% of men by age 60 and ~90% by age 85. Symptoms are classified using the
International Prostate Symptom Score (IPSS).
IPSS Classification
IPSS Score Severity Recommended Management Approach
0–7 Mild Watchful waiting + lifestyle modification
8 – 19 Moderate Pharmacotherapy ± lifestyle modification
20 – 35 Severe Pharmacotherapy; consider surgical referral
3A. Pharmacological Management of BPH
Alpha-1 Adrenergic Blockers (First-Line)
Mechanism: Relax smooth muscle in the prostate and bladder neck → improved urinary flow. Onset of action: 1–2
weeks. Do NOT lower PSA.
Drug Dose Key Advantages Adverse Effects Notes
Tamsulosin 0.4 mg OD Uroselective; fewer Retrograde ejaculation, Most prescribed;
(Flomax) (post-meal) cardiovascular SE dizziness, rhinitis first choice in Nigeria
Alfuzosin 10 mg OD Cardio-neutral; Dizziness, fatigue Take after same
(extended) good for elderly meal daily
Silodosin 8 mg OD Highly uroselective Retrograde ejaculation Avoid in severe
(very common) renal impairment
Doxazosin 1–8 mg OD Also treats HTN Orthostatic hypotension; Titrate slowly;
first-dose syncope bedtime dosing
Terazosin 1–10 mg OD Dual: BPH + HTN Dizziness, asthenia Start 1 mg;
titrate over weeks
■ INTRAOPERATIVE FLOPPY IRIS SYNDROME: Always ask patients if they are scheduled for cataract surgery
before starting alpha-blockers (especially tamsulosin). Inform the ophthalmologist.
5-Alpha Reductase Inhibitors (5-ARIs) — For Enlarged Glands
Mechanism: Block conversion of testosterone → DHT → reduces prostate volume by 20–30%. Onset: 3–6 months
for symptom benefit. Reduces PSA by ~50% — important for interpretation.
Drug Dose Prostate Size Target Key Effects ADRs
Finasteride 5 mg OD > 30 mL Reduces volume; Decreased libido, ED,
lowers PSA 50% gynecomastia, ejaculatory disorder
Dutasteride 0.5 mg OD > 30 mL Dual inhibitor (Type 1+2); Similar to finasteride;
more complete suppression slightly higher gynecomastia
Note: Combination therapy (alpha-blocker + 5-ARI) is indicated for moderate-severe BPH with large prostates (>40 mL). The
CombAT and MTOPS trials confirmed superior outcomes over monotherapy.
For professional use only. Always individualise therapy. Refer appropriately. Page 5
PROSTATE HEALTH — COMMUNITY PHARMACIST GUIDE CLINICAL REFERENCE 2025
Phosphodiesterase-5 Inhibitors (PDE5i) — Dual BPH + ED Benefit
Tadalafil 5 mg OD is the only PDE5 inhibitor with an approved indication for BPH-LUTS. It is particularly useful in
patients who also have erectile dysfunction (common comorbidity). Contraindicated with nitrates. Monitor for
hypotension.
Muscarinic Antagonists — For Overactive Bladder Component
When irritative symptoms (frequency, urgency, nocturia) predominate after outlet obstruction is managed, add an
antimuscarinic agent. Use cautiously — can precipitate urinary retention in severe BPH.
Drug Dose Selectivity Cautions
Solifenacin 5–10 mg OD M3-selective Avoid if PVR > 200 mL; constipation, dry mouth
Tolterodine 4 mg OD (ER) Non-selective Lower CNS effects with ER formulation
Oxybutynin 5 mg BD-TDS Non-selective Highest anticholinergic burden; avoid in elderly
Mirabegron (Beta-3 agonist) 50 mg OD Beta-3 agonist Safe alternative; monitor BP; fewer anticholinergic SE
(not antimuscarinic)
For professional use only. Always individualise therapy. Refer appropriately. Page 6
PROSTATE HEALTH — COMMUNITY PHARMACIST GUIDE CLINICAL REFERENCE 2025
4. PROSTATITIS — TYPES & PHARMACOLOGICAL TREATMENT
Prostatitis is classified by the NIH into four categories. Correct classification determines the antimicrobial strategy
and duration.
Category Type Features First-Line Treatment Duration
I Acute Bacterial Fever, chills, perineal pain, Ciprofloxacin 500 mg BD 2–4 weeks
severe dysuria, elevated WBC or Co-trimoxazole (IV if severe)
II Chronic Bacterial Recurrent UTIs, mild LUTS, Ciprofloxacin 500 mg BD 4–6 weeks
normal exam between episodes or Levofloxacin 500 mg OD (minimum)
IIIa Chronic Pelvic Pain Pelvic pain > 3 months; Alpha-blocker + NSAID; 6–12 weeks
(Inflammatory) WBC in EPS but no bacteria Course of fluoroquinolone multimodal
(4–6 wks trial)
IIIb Chronic Pelvic Pain Pelvic pain; no WBC, Alpha-blocker; Long-term;
(Non-inflammatory) no bacteria in EPS Pelvic floor PT; multidisciplinary
Neuromodulation
IV Asymptomatic Incidental WBC in EPS; Usually no treatment N/A
Inflammatory no patient symptoms required
Nigeria-Specific Note: Fluoroquinolone resistance is rising. For recurrent or refractory cases, send midstream
urine (MSU) and expressed prostatic secretions (EPS) for culture and sensitivity. Doxycycline 100 mg BD for 4
weeks is an alternative for atypical organisms (Chlamydia, Mycoplasma).
For professional use only. Always individualise therapy. Refer appropriately. Page 7
PROSTATE HEALTH — COMMUNITY PHARMACIST GUIDE CLINICAL REFERENCE 2025
5. PROSTATE CANCER — PHARMACIST'S PERSPECTIVE
As a community pharmacist, your role in prostate cancer is supportive: ensuring medication adherence, monitoring
for adverse effects, counselling on androgen deprivation therapy (ADT) side effects, and coordinating referrals.
You are not the prescriber of oncological therapy — but you are the patient's most accessible healthcare
professional.
Hormone Therapy (Androgen Deprivation Therapy — ADT)
Class Drugs Mechanism Key ADRs to Monitor
GnRH Agonists Leuprolide, Goserelin, Initial surge then Hot flushes, osteoporosis, CV risk,
Triptorelin testosterone castration metabolic syndrome, ED, fatigue
GnRH Antagonists Degarelix, Relugolix Immediate testosterone Injection site reactions;
suppression; no flare fewer CV events (relugolix oral)
Anti-Androgens Bicalutamide, Block androgen receptor Gynaecomastia, liver toxicity,
Enzalutamide, Apalutamide seizure risk (enzalutamide)
CYP17 Inhibitors Abiraterone acetate Blocks androgen synthesis Must co-administer with
at adrenal + tumour level prednisone; monitor BP, K+, LFTs
ADT Complication Management — Pharmacist Interventions
• Osteoporosis: Recommend calcium (1000–1200 mg/day) + Vitamin D3 (800–1000 IU/day). Bisphosphonates
(alendronate 70 mg weekly or zoledronic acid IV annually) for high-risk patients.
• Hot Flushes: Venlafaxine 37.5–75 mg OD, medroxyprogesterone acetate, or gabapentin 300 mg TDS have
evidence.
• Metabolic Syndrome: Counsel on diet, exercise, weight. Monitor fasting glucose, lipids every 3–6 months on
ADT.
• Cardiovascular Risk: ADT increases CV risk. Ensure BP control, smoking cessation, statin use if indicated.
• Anaemia: ADT can suppress erythropoiesis. Check FBC; refer if Hb < 10 g/dL.
• Depression/Cognitive effects: Screen with PHQ-9 at each visit. Refer to mental health support as needed.
For professional use only. Always individualise therapy. Refer appropriately. Page 8
PROSTATE HEALTH — COMMUNITY PHARMACIST GUIDE CLINICAL REFERENCE 2025
6. NON-PHARMACOLOGICAL INTERVENTIONS
Bladder Training
• Scheduled voiding: urinate on a fixed schedule (e.g., every 2–3 hours) regardless of urge
• Urge suppression techniques: distraction, deep breathing, pelvic floor contraction when urge hits
• Gradually increase intervals by 15–30 minutes each week until voiding every 3–4 hours
• Keep a bladder diary for the first 2 weeks to identify patterns and triggers
Pelvic Floor Exercises (Kegel Exercises)
Kegel exercises strengthen the external urinary sphincter and pelvic floor muscles, directly addressing urinary
incontinence and urgency. They are especially effective post-intervention but benefit BPH patients significantly.
• Identification: Instruct patient to stop urine midstream to identify the correct muscle group
• Technique: Contract pelvic floor muscles for 5 seconds, relax for 5 seconds. Repeat ×10
• Frequency: 3 sets of 10 repetitions, 3 times daily
• Progression: Increase hold time to 10 seconds over 4–6 weeks
• Positions: Can be done lying, sitting, or standing — integrate into daily routine
• Timeline: Measurable improvement expected within 6–12 weeks of consistent practice
Double Voiding Technique
• After voiding, patient waits 1–2 minutes, then tries to void again
• Helps empty residual urine and reduces post-void dribble and overflow incontinence
• Particularly helpful in patients with significant post-void residual (PVR)
Urethral Milking
After voiding, the patient uses a finger to apply firm pressure behind the scrotum (perineum) and draws forward to
the base of the penis. This mechanically empties the bulbar urethra of remaining urine, reducing post-void dribble.
Surgical Options — For Referral Awareness
Procedure Abbreviation When Indicated Notes
Transurethral Resection of Prostate TURP Gold standard for moderate-severe BPH Most commonly performed
Laser Prostatectomy (HoLEP/GreenLight) — Large prostates; anticoagulated patients Less bleeding; quicker recovery
Prostatic Urethral Lift UroLift Younger patients; preserve ejaculatory function
Minimally invasive
Robotic-Assisted Radical Prostatectomy RARP Localised prostate cancer Specialist oncology centre
Transurethral Needle Ablation TUNA Moderate BPH; poor surgical candidates Office-based procedure
For professional use only. Always individualise therapy. Refer appropriately. Page 9
PROSTATE HEALTH — COMMUNITY PHARMACIST GUIDE CLINICAL REFERENCE 2025
7. LIFESTYLE MODIFICATIONS
Fluid Management
• Total fluid intake: 1.5–2 litres/day — not more (excess worsens urgency and nocturia)
• Fluid timing: Reduce intake after 6 PM to minimise nocturia
• Caffeine reduction: Limit to 1 cup daily — caffeine is a bladder irritant and mild diuretic
• Alcohol: Reduce or eliminate — causes diuresis and irritates bladder mucosa
• Carbonated beverages: Avoid — worsen irritative urinary symptoms
• Spicy foods and citrus: Can irritate bladder; trial elimination if symptoms worsen after meals
Physical Activity
• Aerobic exercise: 150 minutes/week of moderate activity (brisk walking, cycling) — reduces BPH progression
risk by 25%
• Avoidance of prolonged sitting: Sitting compresses the prostate; take breaks every 45–60 minutes
• Cycling caution: Narrow bicycle seats can compress the perineum — use a wider, padded seat if cycling
regularly
• Weight management: Obesity increases DHT levels and BPH severity; target BMI < 25 kg/m2
• Avoid heavy lifting and straining: Increases intra-abdominal pressure and worsens symptoms
Bowel Health
• Constipation worsens LUTS by increasing pressure on the prostate and bladder
• High-fibre diet (25–30 g/day): vegetables, whole grains, legumes
• Adequate hydration supports stool softness without excess fluid burden
• Refer to physician for laxative use if chronic constipation is a problem
Sleep & Stress Management
• Nocturia is frequently worsened by poor sleep quality — address sleep hygiene
• Stress activates the sympathetic nervous system, increasing bladder neck tone and worsening LUTS
• Recommend mindfulness-based stress reduction, yoga, or progressive muscle relaxation
• Screen for obstructive sleep apnoea — it causes nocturnal polyuria and nocturia independently
Sexual Activity
• Regular ejaculation (2–3×/week) may have a protective role in reducing prostatitis symptoms
• Counsel that some BPH medications (tamsulosin, silodosin) cause retrograde ejaculation — this is harmless but
should be disclosed
• ED is common in BPH patients; tadalafil 5 mg OD addresses both simultaneously
For professional use only. Always individualise therapy. Refer appropriately. Page 10
PROSTATE HEALTH — COMMUNITY PHARMACIST GUIDE CLINICAL REFERENCE 2025
8. DIETARY & NUTRACEUTICAL GUIDANCE
Evidence-Based Dietary Patterns
The Mediterranean Diet has the strongest evidence for prostate health — associated with lower BPH severity,
reduced prostate cancer risk, and better overall urological outcomes.
Food Category Recommended Limit / Avoid Reason
Vegetables Tomatoes (cooked), broccoli, Processed vegetables Lycopene (tomatoes) reduces
cauliflower, spinach prostate cancer risk by ~30%
Fats Olive oil, avocado, fatty fish Red meat, processed meats, Omega-3 anti-inflammatory;
(salmon, mackerel) saturated animal fat red meat promotes IGF-1
Soy Tofu, tempeh, soy milk Excess supplemental Phytoestrogens may reduce
(moderate) isoflavones prostate cancer risk
Dairy Low-fat fermented dairy High-fat dairy, excess milk High-fat dairy linked to
(yoghurt, kefir) increased prostate cancer risk
Grains Whole grains, oats, brown rice Refined carbohydrates, Reduces insulin resistance
white bread, sugar and IGF-1 levels
Green Tea 3–4 cups/day (if tolerated) Excess caffeine concern EGCG catechins have
antiproliferative properties
Pomegranate Fresh juice or extract — Reduces PSA velocity;
antioxidant properties
Nutraceuticals — Evidence Summary
Supplement Dose Evidence Level Proposed Mechanism Recommendation
Saw Palmetto 320 mg OD Moderate (conflicting Inhibits 5-alpha reductase; Can use; monitor response
(Serenoa repens) in recent RCTs) anti-inflammatory at 3 months
Beta-Sitosterol 60–130 mg/day Moderate Plant sterol; Reasonable adjunct
improves urine flow
Pygeum africanum 100 mg OD Moderate Anti-inflammatory; Good tolerability;
or 50 mg BD reduces prolactin binding supports African use
Lycopene 15–30 mg/day Moderate–good Antioxidant; reduces Encourage dietary source
prostate cell proliferation (cooked tomatoes) first
Selenium 200 mcg/day Low–moderate Antioxidant cofactor Do NOT supplement in
(SELECT trial negative) excess — may be harmful
Vitamin D3 1000–2000 IU/day Moderate Anti-tumour; VDR Supplement if deficient;
expression in prostate common in Nigeria
Zinc 11–15 mg/day Low Prostate cell regulation From food only; excess
(dietary) zinc is harmful
Stinging Nettle Root 120 mg BD Low–moderate Binds SHBG; Adjunct; generally safe
possible anti-proliferative
Note: Always ask patients about herbal/supplement use — saw palmetto and beta-sitosterol may interact with anticoagulants.
Advise purchasing from reputable sources only; supplement quality varies widely.
For professional use only. Always individualise therapy. Refer appropriately. Page 11
PROSTATE HEALTH — COMMUNITY PHARMACIST GUIDE CLINICAL REFERENCE 2025
9. PATIENT COUNSELLING FRAMEWORK
AIDET Framework for Prostate Counselling: Acknowledge the patient's concerns respectfully (sensitive topic for
men). Inform clearly at appropriate health literacy level. Discuss test results, options, and next steps. Empower
with lifestyle and self-management tools. Thank and schedule a follow-up.
Key Messages to Deliver to This Patient
About PSA Testing:
Explain that a PSA test measures a protein made by the prostate gland. A higher result does not automatically
mean cancer — it can be raised by many other things including enlargement of the prostate, inflammation, or even
vigorous activity. The result will guide next steps.
About Urinary Incontinence:
Reassure the patient that persistent urinary leakage after a UTI/STI has cleared is likely related to the prostate
gland affecting bladder control — not a sign of weakness or permanent damage. This is very common in men over
50 and is treatable.
About BPH (if confirmed):
Benign Prostatic Hyperplasia means the prostate has grown larger, squeezing the tube that carries urine out of the
body. This is not cancer. It does not become cancer. Treatment is very effective and most men manage it very well
with medication and lifestyle changes.
About Medications:
If alpha-blockers are prescribed, explain that they work by relaxing muscle around the bladder outlet. He may feel
slightly dizzy when standing up, especially in the first few days. Take the tablet with food. Some patients notice a
change in ejaculation — semen may go backward into the bladder. This is harmless.
About Sexual Function:
Address this proactively — men often worry but don't ask. BPH medications can affect ejaculation but not
necessarily erection. If sexual function is important to him, tadalafil 5 mg daily may be an option to discuss with his
doctor, as it helps both BPH and erectile function.
About Cancer Screening:
If PSA is elevated, do not use the word 'cancer' prematurely. Explain that further evaluation (possibly an MRI,
repeat PSA, or urology referral) will clarify things. Early detection, if cancer is present, greatly improves outcomes.
Medication Adherence Counselling Points
• Alpha-blockers: Take at the same time daily. Do not stop abruptly without medical advice.
• 5-ARIs (finasteride/dutasteride): Requires 3–6 months before full benefit. Patients often stop early — emphasise
patience.
• 5-ARIs are teratogenic: Pregnant women must NOT handle crushed tablets — advise patient if applicable.
• Combination therapy: Both drugs work differently; taking both is intentional and not a mistake.
• Overactive bladder medications: Dry mouth is expected; can use sugarless gum. Report difficulty urinating
immediately.
For professional use only. Always individualise therapy. Refer appropriately. Page 12
PROSTATE HEALTH — COMMUNITY PHARMACIST GUIDE CLINICAL REFERENCE 2025
10. MONITORING & FOLLOW-UP SCHEDULE
Parameter Frequency Action Threshold
PSA (untreated BPH) Annually Rise > 0.75 ng/mL/yr → urology referral
PSA (on 5-ARI) 6 months, then annually Any rise above baseline on treatment → red flag
IPSS Questionnaire Every 3–6 months Score worsening → reassess therapy
Post-Void Residual (PVR) Baseline + annually > 300 mL → urological assessment
Renal Function (U&Es) Annually Elevated creatinine → upper tract obstruction suspected
Blood Pressure Each visit if on alpha-blocker SBP < 90 mmHg → dose reduce
Liver Function Tests 6-monthly (5-ARIs, bicalutamide) ALT/AST > 3× ULN → discontinue
Bone Density (DEXA) Baseline + 2-yearly (ADT) T-score < -2.5 → bisphosphonate
Fasting Glucose + Lipids 6-monthly (on ADT) Manage as per NCEP guidelines
Full Blood Count 6-monthly (on ADT) Hb < 10 g/dL → investigate, refer
Digital Rectal Exam (DRE) Annually (physician) New nodule/asymmetry → urgent referral
For professional use only. Always individualise therapy. Refer appropriately. Page 13
PROSTATE HEALTH — COMMUNITY PHARMACIST GUIDE CLINICAL REFERENCE 2025
11. RED FLAGS & REFERRAL TRIGGERS
When in doubt, refer early. As a community pharmacist, your strength is in early identification of warning signs
and ensuring the patient gets to the right specialist promptly.
URGENT — Same Day Referral / Emergency
• Acute urinary retention (cannot pass urine at all — painful, distended bladder)
• Haematuria (blood in urine) — especially painless and macroscopic
• Acute severe flank pain with oliguria (suggests obstructive uropathy)
• High fever + rigors + severe dysuria (acute bacterial prostatitis → risk of sepsis)
• PSA > 20 ng/mL on first test
• Symptoms of spinal cord compression back pain + leg weakness + urinary/bowel changes
URGENT — Urology Referral within 2 weeks
• Rapidly rising PSA (> 0.75 ng/mL/year) on any treatment
• New hard, irregular, or asymmetric prostate on DRE
• Suspicious MRI findings or high free/total PSA ratio
• Failure of first-line BPH therapy after 3 months at adequate dose
• Post-void residual > 300 mL consistently on bladder scan
• Recurrent UTIs in men (twice or more in 6 months)
ROUTINE — Urology Referral (within 4–8 weeks)
• PSA 4–10 ng/mL in patient aged 50–70 for further evaluation
• Moderate-to-severe IPSS (≥ 8) not improving with conservative management
• Patient requests surgical option or is uncomfortable with long-term medication
• Suspected CPPS requiring specialist multidisciplinary input
• Young patient (< 45 yrs) with significant LUTS for baseline assessment
For professional use only. Always individualise therapy. Refer appropriately. Page 14
PROSTATE HEALTH — COMMUNITY PHARMACIST GUIDE CLINICAL REFERENCE 2025
12. QUICK-REFERENCE DRUG INTERACTION TABLE
Key drug interactions relevant to prostate medications that a community pharmacist must screen for:
Prostate Drug Interacting Drug/Class Effect Management
All Alpha-Blockers Antihypertensives, PDE5 inhibitors,Severe hypotension; Avoid concurrent PDE5i except tadalafil (dose-separate); monito
diuretics syncope risk
Tamsulosin Strong CYP3A4 inhibitors Increased tamsulosin Avoid combination;
(ketoconazole, ritonavir) levels + toxicity monitor closely if essential
Finasteride/Dutasteride No major interactions Hepatically metabolised; Check LFTs baseline;
(CYP3A4) use with caution in liver disease
Bicalutamide Warfarin Enhanced anticoagulant Monitor INR weekly initially;
effect adjust warfarin dose
Abiraterone Docetaxel, strong CYP2D6 substrates
Increased substrate Use alternative drugs;
(e.g. metoprolol, codeine) levels reduce substrate dose
Ciprofloxacin Antacids, iron, zinc, dairy Significantly reduces Separate by ≥ 2 hours;
(Prostatitis) ciprofloxacin absorption take ciprofloxacin first
Ciprofloxacin Tizanidine, theophylline, Increases drug levels; Avoid tizanidine;
warfarin toxicity risk monitor theophylline + INR
Muscarinic Antagonists Other anticholinergics Additive anticholinergic Use minimum necessary;
(TCAs, antihistamines) toxicity consider mirabegron instead
Tadalafil 5mg (BPH) Nitrates (all forms) LIFE-THREATENING ABSOLUTE CONTRAINDICATION — never combine
hypotension
DISCLAIMER: This guide is intended as a practical reference for qualified healthcare professionals. It does not replace
clinical judgment, local formulary guidelines, or specialist advice. Individualise all therapeutic decisions. Refer patients
appropriately. Compiled with reference to EAU Guidelines on Non-neurogenic Male LUTS (2024), AUA BPH Guidelines
(2023), and WHO Model Formulary.
For professional use only. Always individualise therapy. Refer appropriately. Page 15